The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...
AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...
The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...
WILMINGTON, Del., January 13, 2025--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted ...
The Prescription Drug User Fee Act target date has been set for the third quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback